Gene optimized hantaan virus M segment DNA vaccine for hemorrhagic fever with renal syndrome
AssigneeThe United States of America as represented by the Secretary of the Army
InventorConnie Schmaljohn
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe United States of America as represented by the Secretary of the Army
InventorConnie Schmaljohn
Estimating the term…
A synthetic, codon-optimized Hantaan virus (HTNV) full-length M gene open reading frame that consists of a unique nucleotide sequence encoding HTNV proteins. This synthetic gene was cloned into a plasmid to form the first optimized HTNV full-length M gene that elicits neutralizing antibodies in animals when delivered in combination with a similarly optimized Puumala virus (PUUV) DNA vaccine. The invention obviates the need for an extraneous gene sequence that was previously required for expression of the non-optimized HTNV gene. The synthetic gene is engineered into a molecular vaccine system to prevent hemorrhagic fever with renal syndrome (HFRS) caused by infection with HTNV, SEOV, or DOBV. Alternatively, it can be combined with the optimized PUUV DNA vaccine to protect against HFRS caused by any hantavirus.
A bivalent vaccine for HTNV and PUUV that protects against HFRS caused by HTNV infection comprising a synthetic codon-optimized HTNV full-length M gene open reading frame segment of SEQ ID NO. 1 and PUUV DNA vaccine.
Dependencies are inferred from the claim text.